Zacks Research Has Positive Outlook for BMRN Q4 Earnings

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) - Investment analysts at Zacks Research raised their Q4 2025 earnings estimates for BioMarin Pharmaceutical in a research note issued on Monday, February 17th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will post earnings of $0.67 per share for the quarter, up from their previous estimate of $0.66. The consensus estimate for BioMarin Pharmaceutical's current full-year earnings is $3.15 per share. Zacks Research also issued estimates for BioMarin Pharmaceutical's Q1 2026 earnings at $0.78 EPS.

Several other research firms have also recently weighed in on BMRN. Wolfe Research started coverage on shares of BioMarin Pharmaceutical in a research report on Friday, November 15th. They set an "outperform" rating and a $95.00 price objective on the stock. Bank of America lifted their price objective on BioMarin Pharmaceutical from $99.00 to $103.00 and gave the stock a "buy" rating in a report on Thursday. Piper Sandler increased their price target on shares of BioMarin Pharmaceutical from $122.00 to $126.00 and gave the company an "overweight" rating in a research report on Thursday. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 price objective on shares of BioMarin Pharmaceutical in a research report on Thursday. Finally, StockNews.com raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, February 11th. Seven analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $93.81.

BioMarin Pharmaceutical Price Performance

NASDAQ BMRN traded down $0.48 during trading on Wednesday, reaching $68.25. The company's stock had a trading volume of 2,288,536 shares, compared to its average volume of 1,588,823. The firm has a fifty day moving average of $64.84 and a 200 day moving average of $71.05. BioMarin Pharmaceutical has a one year low of $60.63 and a one year high of $94.85. The stock has a market capitalization of $13.01 billion, a PE ratio of 31.02, a P/E/G ratio of 0.58 and a beta of 0.28. The company has a debt-to-equity ratio of 0.11, a current ratio of 4.27 and a quick ratio of 2.62.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its quarterly earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a net margin of 14.96% and a return on equity of 10.10%. The firm had revenue of $747.31 million during the quarter, compared to analyst estimates of $711.05 million.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in shares of BioMarin Pharmaceutical by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 19,372,185 shares of the biotechnology company's stock valued at $1,273,334,000 after purchasing an additional 93,531 shares during the period. Primecap Management Co. CA raised its holdings in BioMarin Pharmaceutical by 0.4% during the third quarter. Primecap Management Co. CA now owns 18,867,435 shares of the biotechnology company's stock valued at $1,326,192,000 after acquiring an additional 77,350 shares during the period. Dodge & Cox lifted its position in shares of BioMarin Pharmaceutical by 6.1% in the fourth quarter. Dodge & Cox now owns 14,746,235 shares of the biotechnology company's stock valued at $969,270,000 after acquiring an additional 847,917 shares in the last quarter. Capital Research Global Investors boosted its stake in shares of BioMarin Pharmaceutical by 23.8% in the fourth quarter. Capital Research Global Investors now owns 12,991,772 shares of the biotechnology company's stock worth $853,944,000 after acquiring an additional 2,496,817 shares during the period. Finally, Norges Bank purchased a new stake in shares of BioMarin Pharmaceutical during the fourth quarter worth about $234,645,000. 98.71% of the stock is owned by hedge funds and other institutional investors.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.